Article Index
A reading guide to the No-Brainer Biotech series.
Each article in this series examines a document or dataset that exists in plain sight but has not been read carefully by the market. No disease narrative. No investment thesis storytelling. Just primary sources, decoded.
For detailed posts that the other platform can’t easily accommodate.
Encountered over the years during research into controlling inflammation.
An info-share progression from stocktwits to X to substack.
Main Articles
1 - Fix the Tap, Don’t Mop the Flood
The case for InflaRx — and why one forgotten molecule could be the most important anti-inflammatory asset in biotech
An introduction to the C5a signaling pathway, vilobelimab, and INF904 — and why controlling inflammation at its upstream source changes everything.
Why the modern world is killing us from the inside out — and what the leading causes of death are hiding
Three in five deaths globally trace back to chronic inflammation — a public health crisis hiding in plain sight behind named diseases.
3 - HS - The Disease That Hides in Plain Sight
Seven years to diagnosis. Treatments that miss the point. And a molecule that could change both.
Hidradenitis suppurativa — a neutrophil-driven inflammatory disease of the skin — and why every approved treatment targets downstream of the real problem.
4 - PG - The Wound That Shouldn’t Exist
Pyoderma gangrenosum destroys tissue for no reason medicine can explain — and for forty years, the only upstream answer has been ignored.
Pyoderma gangrenosum, the role of C5a and NETosis in its destruction, and why a flawed trial endpoint — not a flawed drug — derailed the first targeted therapy.
5 - AAV - Steroid-Sparing Isn’t Steroid-Free
Reducing steroids was a milestone. Eliminating steroids is the goal. In AAV, no approved drug has crossed that line.
ANCA-associated vasculitis, the limits of avacopan, and the pharmacological case for INF904 as the first drug capable of achieving true steroid-free remission.
6 - ARDS - The Body Sets Itself on Fire
A drug approved in Europe. An ICU full of dying patients. A bureaucratic wall between the two.
Acute respiratory distress syndrome, the neutrophil-driven lung destruction at its core, and why a fully approved drug is sitting unused while patients die.
7 - DKD - The Kidney Nobody’s Looking At
Diabetic kidney disease is the leading cause of kidney failure worldwide. The standard of care slows it. It does not stop it...yet.
Diabetic kidney disease, the C5a-C5aR1 signaling that drives its progression, and why INF904 may offer the first mechanism capable of altering its course.
8 - IgAN - The Young Kidney Claimed By An Ancient Protein
Complement inhibition confirmed, a drug approved, still a flood.
IgA nephropathy, the complement activation that drives it, and why blocking complement upstream may be the answer a newly approved drug class is still only partially providing.
9 - LN - When the Body Attacks Itself
Three drugs approved. Six in ten patients still failing. The upstream trigger nobody has touched.
Lupus nephritis, the classical complement pathway that fires with every flare, and why the molecule initiating each attack has never been targeted in a clinical trial in this disease.
10 - MN - When the Immune System Opens the Floodgates
One million microscopic filters under autoimmune attack. A complement cascade the field has been misreading for fifty years. And an upstream target nobody has tried.
Primary membranous nephropathy, the autoimmune trigger that destroys the kidney’s final filtration barrier, and why no complement inhibitor has ever been tested in the most complement-dependent kidney disease in nephrology.
11 - BP - What Holds the Skin Together for a Lifetime — Until It Doesn’t
Fasteners that give way to unbearable discomfort, and a partial solution in need of an upstream makeover.
Bullous pemphigoid — the most common autoimmune blistering disease in the world, striking at 80 — and why the first approved targeted therapy leaves the upstream complement mechanism that drives the blistering entirely untouched.
12 - SCD - Living With Blood Full of Blades — And Starving Organs
Sixty thousand miles, 25 trillion cells, and every organ in the body held hostage. An upstream solution awaits.
Sickle cell disease, the complement-C5a-neutrophil cascade that converts a genetic quirk into a vascular catastrophe, and why every drug that has tried to prevent it has aimed at the wrong target.
13 - AD - The Forgotten Fire That Burns Throughout
The drug that can stop it must get in before it’s too late — before tens of millions of Alzheimer’s patients unknowingly remain in the flames.
Alzheimer’s disease — the complete inflammatory architecture from gut to brain, the BBB penetration requirement no approved drug meets, and the patent signal pointing to the molecule that could change everything.
14 - PsA - Upstream of the Blockbusters
Psoriatic arthritis has a $10.5 billion price tag that only covers consequences. The cause should be included too.
Psoriatic arthritis — a neutrophil-driven, complement-amplified disease where the skin initiates and the joint pays — and why every approved drug in a $10.5 billion market sits downstream of a signal that has never been blocked at its source.
15 - UC - Biting the Hand That Feeds
Ulcerative colitis will destroy your colon. It may be what you eat — and don't eat — that destroys what protects it.
The neutrophil-dominant IBD that has never had its upstream signal blocked — how C5a drives the mucosal siege, why a $10 billion market valuation for a downstream oral drug signals the commercial opportunity, and what INF904 at Step 1 would mean for the 1.5 million Americans living with a disease the market has never addressed at its source.
The most dangerous skin cancer has a secret: when treatment comes looking, it pulls its survival switch inside the cell — beyond the reach of every approved drug. Until now.
Cutaneous squamous cell carcinoma, the intracellular C5aR1 survival mechanism discovered in 2025, and why a cell-permeable small molecule is the only drug class that can follow the target where it hides.